Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure.

Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

A new oral antiviral drug candidate has been developed for the treatment of diseases caused by orthoparamyxoviruses, such as measles and croup syndrome, according to a study published by researchers at Georgia State University.

Study: New Oral Drug Effective Against Orthoparamyxovirus Diseases, Including Measles

Study Results Position Ensitrelvir as Potential First Oral Antiviral for COVID-19 Post-Exposure Prevention

The landscape of viral prophylaxis is shifting from a reliance on systemic immune priming to targeted molecular intervention. Japan has recently pivoted its clinical strategy by approving the preventive use of Xocova, an oral medication designed to halt the viral replication cycle before symptoms manifest, marking a significant departure from standard post-diagnostic treatment. Key Clinical […]
You can read the full story here:  New Japanese Oral Drug Effectively Prevents Covid .

New Japanese Oral Drug Effectively Prevents Covid

The results mark the first late-stage success for an oral antiviral used to prevent COVID-19 after exposure.

antiviral news

Press Releases in the global landscape